DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Liver Transplant Rejection - Pipeline Review, H1 2017" report to their offering.
Pharmaceutical and Healthcare latest pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.
Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Liver Transplant Rejection - Overview
- Liver Transplant Rejection - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Liver Transplant Rejection - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liver Transplant Rejection - Companies Involved in Therapeutics Development
- Astellas Pharma Inc
- Biogen Inc
- Conatus Pharmaceuticals Inc
- Dompe Farmaceutici SpA
- Novartis AG
- RedHill Biopharma Ltd
For more information about this report visit http://www.researchandmarkets.com/research/r76963/liver_transplant